CA3038106A1 - Compounds and methods for treating lupus - Google Patents

Compounds and methods for treating lupus Download PDF

Info

Publication number
CA3038106A1
CA3038106A1 CA3038106A CA3038106A CA3038106A1 CA 3038106 A1 CA3038106 A1 CA 3038106A1 CA 3038106 A CA3038106 A CA 3038106A CA 3038106 A CA3038106 A CA 3038106A CA 3038106 A1 CA3038106 A1 CA 3038106A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
occurrence
cooh
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3038106A
Other languages
English (en)
French (fr)
Inventor
Fiona Lorraine Scott
Kristen R. Taylor Meadows
Robert Peach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptos LLC
Original Assignee
Celgene International II SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene International II SARL filed Critical Celgene International II SARL
Publication of CA3038106A1 publication Critical patent/CA3038106A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3038106A 2016-09-29 2017-09-28 Compounds and methods for treating lupus Pending CA3038106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401762P 2016-09-29 2016-09-29
US62/401,762 2016-09-29
PCT/US2017/054053 WO2018064356A1 (en) 2016-09-29 2017-09-28 Compounds and methods for treating lupus

Publications (1)

Publication Number Publication Date
CA3038106A1 true CA3038106A1 (en) 2018-04-05

Family

ID=60043386

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3038106A Pending CA3038106A1 (en) 2016-09-29 2017-09-28 Compounds and methods for treating lupus

Country Status (6)

Country Link
US (1) US11278526B2 (https=)
EP (1) EP3518922B1 (https=)
JP (1) JP7086945B2 (https=)
KR (1) KR102408814B1 (https=)
CA (1) CA3038106A1 (https=)
WO (1) WO2018064356A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630738B1 (en) * 2017-05-22 2023-07-19 Egis Gyógyszergyár Zrt. Process for the production of ozanimod
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
EP3947363A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS
CN116332794B (zh) * 2021-12-24 2024-10-15 上海合全药物研发有限公司 一种芳基腈类化合物的制备方法
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
RU2009115963A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
SI2291080T1 (sl) 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
EA024801B1 (ru) * 2009-11-13 2016-10-31 Рецептос Ллк Селективные модуляторы рецептора сфингозин-1-фосфата
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Also Published As

Publication number Publication date
KR102408814B1 (ko) 2022-06-14
KR20190060791A (ko) 2019-06-03
JP7086945B2 (ja) 2022-06-20
EP3518922B1 (en) 2026-02-11
US20190224172A1 (en) 2019-07-25
US11278526B2 (en) 2022-03-22
WO2018064356A1 (en) 2018-04-05
JP2019529487A (ja) 2019-10-17
EP3518922A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
JP2021178852A (ja) Ｈｉｖプロテアーゼ阻害剤としての１−ベンジル−２−イミノ−４−フェニル−５−オキソイミダゾリジン誘導体
EP3518922B1 (en) Compounds and methods for treating lupus
JP5988379B2 (ja) スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
CN110088105B (zh) Jak家族激酶的小分子抑制剂
EA021672B1 (ru) Модуляторы рецепторов сфингозин-1-фосфата и их применение
US11207301B2 (en) Sphingosine 1 phosphate receptor agonists for neuroprotection
JP6987859B2 (ja) Ｍａｇｌ阻害剤
TWI813570B (zh) 作為C5a抑制劑之5-5稠合環
BR112021007861A2 (pt) compostos heterocíclicos substituídos por amida
TW201927782A (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
RU2760303C2 (ru) Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
TW201934552A (zh) 作為C5aR抑制劑之經二芳基取代之5,5-稠合環化合物
TW201742862A (zh) 2－取代之吲唑於治療及預防自體免疫病症之用途
IL233986A (en) History of diaminopyrimidine, their preparation and their pharmaceutical preparations
JP7224293B2 (ja) Ｒｏｒガンマモジュレーター及びその使用
JP2020505412A (ja) Ｒｏｒガンマモジュレーター及びその使用
WO2020077361A1 (en) Compounds and methods of their use
TWI537251B (zh) Ｆｐｒ１拮抗劑的衍生物及其用途
ES2390053T3 (es) Derivado de ácido fenilacético, procedimiento para producir el mismo y uso
JP2020505413A (ja) Ｒｏｒガンマモジュレーター及びその使用
JP2024031105A (ja) 線維症治療又は予防薬
TW201534322A (zh) Ｆｐｒ１拮抗劑的衍生物及其用途（一）

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220830

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251111

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106